News releases

Medtronic Diabetes partners with actress Alexandra Park to share her journey with diabetes technology and how it’s helped her find peace of mind

-January 31, 2024

Actress, writer and producer Alexandra Park, best known for her role on The Royals and Australian series Home and Away, is partnering with Medtronic Diabetes to help others living with type 1 diabetes learn more about advanced technologies that can help make life with the condition easier.

Read more >

Medtronic real-world evidence demonstrates consistent results of the MiniMed™ 780G regardless of demographic or cultural differences

-October 5, 2023

Data shows the successful performance of the AID algorithm under substantial changes to daily routines and lifestyle, including during Ramadan.

Read more >

The MiniMed™ 780G system with Meal Detection™ technology* now available to Medicare beneficiaries

-July 6, 2023

Orders will be processed immediately and shipments will start in the coming weeks.

Read more >

InPen™ Smart Insulin Pen data shows the system’s unique reminders improve treatment outcomes for those using multiple daily injections

-June 23, 2023

Results show that the use of InPen resulted in an increase in Time in Range among those in the studies.

Read more >

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

-June 23, 2023

DUBLIN and SAN DIEGO, June 23, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection™ technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent.

Read more >

Medtronic Diabetes resolves warning letter, clearing path for future innovations

-April 25, 2023

DUBLIN, April 25, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) lifted the warning letter received at the company's Diabetes headquarters in Northridge, California, in December 2021. This follows on the heels of last week's FDA approval of the MiniMed™ 780G system, the world's first and only automated insulin delivery system with meal detection technology* that provides automatic adjustments and corrections to glucose levels every 5 minutes.§

Read more >

FDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§

-April 21, 2023

DUBLIN, April 21, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 780G system with the Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology. This milestone marks the approval of the only system with meal detection technology* that provides automatic adjustments and corrections to sugar levels every 5 minutes§. The system provides insulin to help account for when users occasionally forget to bolus or underestimates the number of carbs in their meal.

Read more >

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.

-November 15, 2022

DUBLIN, Nov. 15, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and only infusion set labelled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.

Read more >

Medtronic leverages data science to launch first-of-its-kind personalized insights program for people living with diabetes

-October 18, 2022

DUBLIN, Oct. 18, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing.

Read more >

CMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps

-December 22, 2021

Medicare coverage for Medtronic customers will be available 60 days after official publication

DUBLIN, Dec. 22, 2021 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes CGMs that integrate with Medtronic insulin pumps. The proposed rule was finalized on December 21, 2021 and will be effective starting 60 days after official publication.

Read more >

View all announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Cho
Sr Director, Global Communications

Ashley Patterson

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits